Navigation Links
Cargill expands support of Notre Dame Haiti Program
Date:12/6/2012

The Notre Dame Haiti Program and Cargill have renewed their partnership to eliminate lymphatic filariasis (LF) in Haiti. LF, also known as elephantiasis, is a mosquito-borne disease that affects over 2 million Haitians and is the second leading cause of long-term disfigurement and disability worldwide. LF is truly a national disease in Haiti and 87 percent of the country is a potential risk zone. In much of coastal Haiti, as much as half of the population is infected with the parasite.

After donating salt to the program two years ago, Cargill is now offering its technical and operations expertise in salt production. Cargill has committed $150,000 over the next three years to the Notre Dame Haiti Program to help establish a sustainable salt-fortification venture in Haiti. The salt is fortified with potassium iodate (iodine) and diethylcarbamazine citrate (DEC) and is designed to stop LF, while also preventing Iodine Deficiency Disorder.

Founded in 1993, the University of Notre Dame Haiti Program seeks to eliminate LF in Haiti by 2020. LF can be eliminated through a Mass Drug Administration and the distribution of co-fortified salt.

The Haiti Program is partnering with the Haitian Ministry of Health, corporations and non-governmental organizations to forever eliminate the disease in Haiti, thus alleviating suffering, helping to grow the Haitian economy, and creating an exportable model for LF elimination throughout the developing world. For more information, visit www.haiti.nd.edu.

Salt fortified with DEC avoids the barriers associated with annual table-based mass treatment. For instance, DEC-fortified salt does not require a dedicated infrastructure, nor is it associated with the adverse side effects (flu-like symptoms) caused by rapid death of the parasite during tablet-based mass treatment.

Iodine Deficiency Disorder is prevalent in Haiti and can stunt both physical and mental develo
'/>"/>

Contact: Gena Robinson
Gena.C.Robinson.90@nd.edu
574-631-6055
University of Notre Dame
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Bioengineered marine algae expands environments where biofuels can be produced
2. Preventice Expands Options for Wireless Patient Monitoring with Qualcomm Life
3. Intersil Expands Precision Analog IC Offerings with Micross Components
4. Research4Life greatly expands peer-reviewed research available to developing world
5. BONESUPPORT für 2012 Top 100 Global Award von Red Herring ausgewählt
6. BONESUPPORT sélectionné en tant que 100 meilleures entreprises mondiales du Red Herring 2012
7. BONESUPPORT Selected As A 2012 Red Herring Top 100 Global
8. $1 million Kenan Trust Grant extends support of Scripps Florida education outreach
9. Renewal grant supports genetic research into arthritis of the spine
10. More evidence needed to support use of autism interventions
11. Academia should fulfill social contract by supporting bioscience startups, case study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... 8, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... members of the executive management team will present at the ... Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company Technology, ... ET Location: The New York Palace Hotel, New ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... (ACT) therapy is used to treat patients with metastatic solid ... cancer cells, and some of their immune T cells. When ... cells that stimulate the T cells to cause an immune ... re-infused into the patient to mount an immunological, anti-cancer response ...
... died in Britain of cancer of the liver. Eventually, researchers ... aflatoxin as the cause of this mysterious 'turkey X' disease. ... most virulent natural carcinogenic substances. , The tasteless toxin is ... arid regions, in the south-west of the US and in ...
... Rutgers University will lead a new $52.7 million research ... play in life's most fundamental processes and point the ... Rutgers Professor Gaetano Montelione, the Northeast Structural Genomics Consortium ... one of the largest in Rutgers' history, will reinforce ...
Cached Biology News:Corn grain mould used as pesticide 2Rutgers to lead $52.7 million protein research program 2Rutgers to lead $52.7 million protein research program 3Rutgers to lead $52.7 million protein research program 4
(Date:6/3/2015)... UK, and BRUSSELS, Belgium (PRWEB) June 03, 2015 ... and beyond, photonics plays an important part in enabling ... the European Commission. Innovation and technology leaders helped bring ... in thematic sessions during the Photonics21 annual meeting ... was a sponsor of the event, held 28 and ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has ... by Product , Test, Application & End User - ... The bioburden testing market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... limit testing market is segmented into consumables and instruments. ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has announced the addition ... by Products - Global Forecast to 2020" report ... is expected to reach $17.0 Billion in 2020 from ... during the forecast period of 2015 to 2020 ... of a range of products for wide applications, decreasing ...
(Date:6/2/2015)... Pa. , June 2, 2015   BioClinica ... and technology provider, today announced that David Peters ... been named Executive Vice President and Chief Financial Officer ... 2015. Peters brings more than 25 years ... pharmaceutical services. "David has extensive and deep knowledge in ...
Breaking Biology Technology:Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2BioClinica Names David Peters New Chief Financial Officer 2
... NEW YORK, April 10 Intellect Neurosciences,Inc. (OTC ... obtained a,Notice of Allowance and completed the grant ... Company,s ANTISENILIN(R) antibodies and,products being developed by the ... the European patent is expected in several weeks. ...
... Va., April 10 Insmed Inc. (Nasdaq:,INSM), a ... of a letter and questionnaire from the Chairman ... Subcommittee on Health,on the possible development of legislation ... Sent to approximately 30 stakeholders in the biotechnology ...
... Product Candidate -, PRINCETON, N.J., April 10, ... and protein production,company, today announced that it has ... Pharmaceuticals, LLC. According to the,agreement, Laureate will produce ... is planned for use in clinical trials, and ...
Cached Biology Technology:Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 2Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 4Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 2Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 3Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
Biology Products: